Drugs Made In America Acquisition II, a blank check company targeting the pharmaceutical industry, filed on Monday with the SEC to raise up to $500 million in an initial public offering.
The company plans to raise $500 million by offering 50 million units at $10. Each unit consists of one share of common stock and one right to receive one-tenth of a share upon the completion of an initial business combination.
Drugs Made In America Acquisition is led by CEO and Chair Lynn Stockwell, the founder and Chair of 2022 direct listing Bright Green (OTC: BGXX; -99% from Nasdaq reference price). The SPAC plans to target businesses in the pharmaceutical industry, focusing on proven industry leaders with defensible and established business models, among other characteristics.
Management's previous SPAC, Drugs Made In America Acquisition (DMAAU), went public this past February.
The Fort Lauderdale, FL-based company was founded in 2024 and plans to list on the Nasdaq under the symbol DMIIU. Drugs Made In America Acquisition II filed confidentially on March 19, 2025. Cantor Fitzgerald is the sole bookrunner on the deal.
